Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HWCRC 740.2, Detroit, MI, 48201, USA.
Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI, 48201, USA.
Mol Cancer. 2021 Nov 18;20(1):149. doi: 10.1186/s12943-021-01446-z.
Although mechanistic studies clarifying the molecular underpinnings of AML have facilitated the development of several novel targeted therapeutics, most AML patients still relapse. Thus, overcoming the inherent and acquired resistance to current therapies remains an unsolved clinical problem. While current diagnostic modalities are primarily defined by gross morphology, cytogenetics, and to an extent, by deep targeted gene sequencing, there is an ongoing demand to identify newer diagnostic, therapeutic and prognostic biomarkers for AML. Recent interest in exploring the role of circular RNA (circRNA) in elucidating AML biology and therapy resistance has been promising. This review discerns the circular RNAs' evolving role on the same scientific premise and attempts to identify its potential in managing AML.
虽然阐明 AML 分子基础的机制研究促进了几种新型靶向治疗药物的开发，但大多数 AML 患者仍会复发。因此，克服对当前治疗方法的固有和获得性耐药性仍然是一个未解决的临床问题。虽然当前的诊断方法主要由大体形态、细胞遗传学和在一定程度上由深度靶向基因测序来定义，但人们仍在不断寻求鉴定 AML 的新型诊断、治疗和预后生物标志物。最近人们对探索环状 RNA（circRNA）在阐明 AML 生物学和治疗耐药性方面的作用产生了兴趣，这一探索很有前景。本综述根据同一科学前提，探讨了环状 RNA 不断变化的作用，并试图确定其在管理 AML 方面的潜力。
